Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
ESMO Open|December 12, 2022
A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR)W Okamoto, K Sakai, A Makiyama, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 6, 2025
Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitisH S Rugo, E Tokunaga, H Iwata, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2020
Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trialK Yamazaki, T Yamanaka, M Shiozawa, et al.
ESMO Gastrointestinal Oncology|May 28, 2026
A phase II study of pembrolizumab plus chemotherapy with short-course radiotherapy as induction treatment for unresectable locally advanced esophageal squamous cell carcinoma: PALADIN trialD Okemoto, D Kotani, M Nakamura, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Temporal dynamics of CLDN18.2 expression following zolbetuximab treatment in advanced gastric cancerK Yamamoto, I Nakayama, N Sakamoto, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Association of PD-L1 and PD-L2 expression and tumor-infiltrating lymphocytes in <i>BRAF</i> V600E-mutated metastatic colorectal cancer: GI-SCREEN <i>post-hoc</i> analysisM Imai, Y Nakamura, T Denda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 3, 2021
Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinomaK Shitara, M Özgüroğlu, Y-J Bang, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Consensus guidance for prevention and management of nausea and vomiting in patients treated with zolbetuximab + chemotherapy: a RAND/UCLA modified Delphi panel studyS J Klempner, R A Pazo-Cid, S Lonardi, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Clinical implementation of simultaneous multiple biomarkers testing for metastatic or recurrent gastroesophageal adenocarcinoma: a single-institutional experienceU Okazaki, I Nakayama, N Sakamoto, et al.
ESMO Open|February 26, 2026
Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinomaK Shitara, Y-J Bang, L S Wyrwicz, et al.
Pageof 8